Stockreport

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Marker Therapeutics, Inc.  (MRKR) 
Last marker therapeutics, inc. earnings: 11/12 04:01 pm Check Earnings Report
PDF Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% [Read more]